BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Manual for Tracking down Special Store Lodgings- 5 State of the art Advancements in Computer generated Simulation
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- Investigating Inside Plan and Home Style: Change Your Residing Space
- Rights groups condemn Israel Police decision to ban Sudan Genocide protests nationwide
- 5 Wellbeing Applications Assist You With remaining Fit
- 2025 Arctic League telethon raises more than $39k
- Trump awarded 1st FIFA Peace Prize by Gianni Infantino at 2026 World Cup draw
- Russian drone slams into block of flats in deadly wave of strikes across Kyiv
